{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
THIOCARBARSONE is an arsenical amoebicide.
Status:
US Previously Marketed
First approved in 1951
Class (Stereo):
CHEMICAL (MIXED)
Status:
US Previously Marketed
Source:
Levo-isomethadone by Winthrop Stearns
(1951)
Source URL:
First approved in 1951
Source:
Levo-isomethadone by Winthrop Stearns
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
US Previously Marketed
Source:
PHENURONE by ABBVIE
(1951)
Source URL:
First approved in 1951
Source:
PHENURONE by ABBVIE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Phenacemide, also known as phenylacetylurea, is an anticonvulsant of the ureide (acetylurea) class. Phenacemide was introduced in 1949 for the treatment of epilepsy, but was eventually withdrawn from the market because of its severe side effects, which includes personality changes, blood, renal and skin disorders.
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Gallamine triethiodide is a synthetic nondepolarizing blocking drug, which is allosteric antagonist of muscarinic M2 acetylcholine receptor and inhibitor of acetylcholinesterase. It was used under brand name flaxedil to stabilize muscle contractions during surgical procedures. However, this usage was discontinued. It was shown, that gallamine caused tachycardia by depressing the vagus nerve and, occasionally, hypertension and increased cardiac output.
Status:
US Previously Marketed
Source:
PAVERIL PHOSPHATE by LILLY
(1961)
Source URL:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Dimoxyline is the synthetic analogue of papaverine, Acute toxicity studies show it to be less toxic than papaverine. No analgesic action and no tolerance development in experimental animals by repeated administration. But Dimoxyline does not appear to be as potent as papaverine in comparable dosage. Dimoxyline is indicated for the treatment of patients with angina pectoris. Also, significant amount of benefit was claimed in patients with acute or chronic phlebitis, arterial thrombosis or embolism, Raynaud’s phenomena and early thromboangiitis obliterans or arteriosclerosis obliterans. Detected adverse events are: nausea or abdominal cramps.
Status:
US Previously Marketed
Source:
DILOR by SAVAGE LABS
(1976)
Source URL:
First approved in 1951
Source:
NEOTHYLLINE by TEVA
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Dyphylline is 7-(2,3-dihydroxypropyl)-theophylline, a white, extremely bitter, amorphous powder that is freely soluble in water and soluble in alcohol. Dyphylline is stable in gastrointestinal fluids over a wide range of pH. Dyphylline is a xanthine derivative with pharmacologic actions similar to theophylline and other members of this class of drugs. Its primary action is that of bronchodilation, but it also exhibits peripheral vasodilatory and other smooth muscle relaxant activity to a lesser degree. The bronchodilatory action of dyphylline, as with other xanthines, is thought to be mediated through competitive inhibition of phosphodiesterase with a resulting increase in cyclic AMP producing relaxation of the bronchial smooth muscle. Dyphylline exerts its bronchodilatory effects directly and, unlike theophylline, is excreted unchanged by the kidneys without being metabolized by the liver. Because of this, dyphylline pharmacokinetics and plasma levels are not influenced by various factors that affect liver function and hepatic enzyme activity, such as smoking, age, congestive heart failure, or concomitant use of drugs which affect liver function.
Status:
US Previously Marketed
Source:
BANTHINE by SHIRE
(1951)
Source URL:
First approved in 1951
Source:
BANTHINE by SHIRE
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Methantheline is a synthetic quarternary ammonium antimuscarinic used to relieve cramps or spasms of the stomach, intestines, and bladder. It is indicated for the treatment of peptic ulcer disease, irritable bowel syndrome, pancreatitis, gastritis, biliary dyskinesia, pylorosplasm, and reflex neurogenic bladder in children. It can be used together with antacids or other medicines, such as H2-receptor antagonists, in the treatment of peptic ulcer. Methantheline bromide (diethyl-methyl [2-(9 xanthenyl carbonyloxy) ethyl] ammonium bromide) is marketed to treat neurogenic bladder instability. In comparison with atropine, it influences the parasympathetic nervous transmission more by ganglionic rather than peripheral muscarinic receptor blockade. Methantheline inhibits the muscarinic actions of acetylcholine on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. Clinical effects after single therapeutic doses of 50-100 mg last for about 6 hours which is longer than after atropine. The drug relaxes smooth muscles of the gastrointestinal and urogenital tract. Furthermore, it inhibits bronchial, salivary and sweat glands secretion, lowers the production of gastric juice and disturbs accommodation. A recent randomised double-blind placebo-controlled study using a new commercial preparation of methantheline bromide (Vagantin, Germany) demonstrated significant sweat reduction and was evaluated as is an effective and safe treatment of axillary hyperhidrosis.
Status:
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
IOTHIOURACIL, in a form of sodium salt, was used as an antithyroid agent in the treatment of hyperthyroidism. It is selectively incorporated into the melanin pigment of melanomas during biosynthesis by serving as false melanin precursors. Radiolabelled (125I) IOTHIOURACIL may be used as a radiopharmaceutical for diagnosis and therapy of melanotic melanomas.
Status:
US Previously Marketed
First approved in 1951
Class (Stereo):
CHEMICAL (ACHIRAL)